Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Management of cancer and health after the clinic visit: A call to action for self-management in cancer care

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Chromosomal Abnormalities in Offspring of Young Cancer Survivors: A Population-Based Cohort Study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cytoplasmic mRNPs revisited: Singletons and condensates

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elevated miR-9 in Cerebrospinal Fluid Is Associated with Poor Functional Outcome After Subarachnoid Hemorrhage

    Research output: Contribution to journalJournal articleResearchpeer-review

  • GEMO Study Collaborators
View graph of relations

BACKGROUND: BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains unclear.

METHODS: We used Mendelian randomization approaches to evaluate the association of height and BMI on breast cancer risk, using data from the Consortium of Investigators of Modifiers of BRCA1/2 with 14 676 BRCA1 and 7912 BRCA2 mutation carriers, including 11 451 cases of breast cancer. We created a height genetic score using 586 height-associated variants and a BMI genetic score using 93 BMI-associated variants. We examined both observed and genetically determined height and BMI with breast cancer risk using weighted Cox models. All statistical tests were two-sided.

RESULTS: Observed height was positively associated with breast cancer risk (HR = 1.09 per 10 cm increase, 95% confidence interval [CI] = 1.0 to 1.17; P = 1.17). Height genetic score was positively associated with breast cancer, although this was not statistically significant (per 10 cm increase in genetically predicted height, HR = 1.04, 95% CI = 0.93 to 1.17; P = .47). Observed BMI was inversely associated with breast cancer risk (per 5 kg/m2 increase, HR = 0.94, 95% CI = 0.90 to 0.98; P = .007). BMI genetic score was also inversely associated with breast cancer risk (per 5 kg/m2 increase in genetically predicted BMI, HR = 0.87, 95% CI = 0.76 to 0.98; P = .02). BMI was primarily associated with premenopausal breast cancer.

CONCLUSION: Height is associated with overall breast cancer and BMI is associated with premenopausal breast cancer in BRCA1/2 mutation carriers. Incorporating height and BMI, particularly genetic score, into risk assessment may improve cancer management.

Original languageEnglish
JournalNational Cancer Institute. Journal (Online)
Volume111
Issue number4
Pages (from-to)350-364
Number of pages15
ISSN1460-2105
DOIs
Publication statusPublished - 1 Apr 2019

ID: 59011102